Production (Stage)
Neuphoria Therapeutics Inc.
NEUP
$6.87
-$0.28-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 7.40K |
| Total Other Revenue | -- | -- | -- | -95.70K | -44.20K |
| Total Revenue | -- | -- | -- | -95.70K | -44.20K |
| Cost of Revenue | -- | -- | -- | 3.74M | 2.74M |
| Gross Profit | -- | -- | -- | -3.79M | -2.79M |
| SG&A Expenses | -- | -- | -- | 8.28M | 9.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 16.59M | 18.12M |
| Operating Income | -- | -- | -- | -16.63M | -18.17M |
| Income Before Tax | -- | -- | -- | -15.49M | -18.19M |
| Income Tax Expenses | -- | -- | -- | -61.30K | -88.20K |
| Earnings from Continuing Operations | -- | -- | -- | -15.42 | -18.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -15.42M | -18.10M |
| EBIT | -- | -- | -- | -16.63M | -18.17M |
| EBITDA | -- | -- | -- | -16.03M | -17.59M |
| EPS Basic | -- | -- | -- | -8.15 | -8.15 |
| Normalized Basic EPS | -- | -- | -- | -5.11 | -5.11 |
| EPS Diluted | -- | -- | -- | -8.15 | -8.15 |
| Normalized Diluted EPS | -- | -- | -- | -5.11 | -5.11 |
| Average Basic Shares Outstanding | -- | -- | -- | 3.39B | 3.08B |
| Average Diluted Shares Outstanding | -- | -- | -- | 3.39B | 3.08B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |